Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

PROF
Profound Medical Corp. Common Stock
stock NASDAQ

At Close
Jun 23, 2025 3:59:34 PM EDT
6.07USD-4.409%(-0.28)22,036
0.00Bid   0.00Ask   0.00Spread
Pre-market
0.00USD-100.000%(-6.35)0
After-hours
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 18, 2022
07:41AM EST  Profound Medical Announces First Patients Treated In Prospective, Randomized Clinical Trial Comparing The TULSA Procedure To Radical Prostatectomy   Benzinga
07:34AM EST  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the first patients have been treated in the Level 1 CAPTAIN trial.   GlobeNewswire Inc
Jan 5, 2022
08:00AM EST  Kenneth Knudson Joins Profound Medical as Chief Commercial Officer   GlobeNewswire Inc
Nov 5, 2021
09:28AM EDT  Profound Medical Q3 EPS $(0.29) Misses $(0.28) Estimate, Sales $2.50M Miss $3.87M Estimate   Benzinga
Nov 4, 2021
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Nov 1, 2021
04:30PM EDT  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in two investor conferences in November.   GlobeNewswire Inc
Oct 18, 2021
04:45PM EDT  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2021 financial results after market close on Thursday, November 4, 2021.   GlobeNewswire Inc
Sep 8, 2021
04:30PM EDT  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announce today that management will participate in two investor conferences in September.   GlobeNewswire Inc
Aug 4, 2021
04:34PM EDT  Profound Medical Q2 EPS $(0.35) Misses $(0.26) Estimate, Sales $2.60M Beat $2.27M Estimate   Benzinga
04:05PM EDT  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2021.   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 4, 2021   Benzinga
Jul 15, 2021
04:30PM EDT  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2021 financial results after market close on Wednesday, August 4, 2021.   GlobeNewswire Inc
May 25, 2021
04:30PM EDT  Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in two investor conferences in June.   GlobeNewswire Inc
May 19, 2021
04:30PM EDT  Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (Profound or the Company) is pleased to announce the voting results from its Annual Meeting of Shareholders that was held today (the Meeting). A total of 11,810,287 common shares, representing 58.044% of the common shares outstanding, were represented in person and by proxy at the Meeting.   GlobeNewswire Inc
May 13, 2021
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 12, 2021
04:35PM EDT  Profound Medical Q1 EPS $(0.37) Down From $(0.21) YoY, Sales $711.00K Down From $1.16M YoY   Benzinga
04:14PM EDT  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2021.   GlobeNewswire Inc
04:22AM EDT  Earnings Scheduled For May 12, 2021   Benzinga
May 6, 2021
07:17AM EDT  Profound Medical Says Enters Into U.S. Multi-Center Commercial Agreement With Akumin For TULSA-PRO   Benzinga
07:00AM EDT  Profound Medical and Akumin Enter into U.S. Multi-Center   GlobeNewswire Inc
Apr 21, 2021
04:30PM EDT  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2021 financial results after market close on Wednesday, May 12, 2021.   GlobeNewswire Inc
Apr 14, 2021
04:30PM EDT  Profound Medical to Participate in the 2021 Bloom Burton & Co.   GlobeNewswire Inc
Mar 3, 2021
07:00AM EST  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today the appointment of Cynthia Lavoie Ph.D., MBA, to its Board of Directors.   GlobeNewswire Inc
Mar 2, 2021
04:08PM EST  Profound Medical Q4 EPS $(0.38) Down From $(0.33) YoY, Sales $2.90M Up From $2.13M YoY   Benzinga
04:02PM EST  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2020.   GlobeNewswire Inc
03:40AM EST  Earnings Scheduled For March 2, 2021   Benzinga
Feb 11, 2021
04:30PM EST  Profound Medical to Participate in the BTIG Virtual MedTech,   GlobeNewswire Inc
Feb 9, 2021
04:30PM EST  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2020 financial results after market close on Tuesday, March 2, 2021.   GlobeNewswire Inc
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 3, 2021
07:31AM EST  The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision   Benzinga
Jan 26, 2021
08:07AM EST  The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market   Benzinga
Jan 22, 2021
07:22AM EST  The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa   Benzinga
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 5, 2021
04:31PM EST  Profound Medical Sees Prelim. Q4 Sales ~$3.7M, Up 32% YoY; Sees FY20 Sales $9.7M, Up From $5.5M YoY   Benzinga
04:30PM EST  Profound Medical Announces Preliminary Unaudited Fourth Quarter   GlobeNewswire Inc
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 21, 2020
07:30AM EST  Profound Medical Signs Agreement with GE Healthcare to Expand   GlobeNewswire Inc
Nov 30, 2020
08:06AM EST  Profound Medical Receives FDA HDE Approval For Sonalleve   Benzinga
08:00AM EST  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company) announced today that Sonalleve has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE) for the treatment of osteoid osteoma.   GlobeNewswire Inc
07:45AM EST  Profound Medical Announces Changes to its Board of Directors   GlobeNewswire Inc
Nov 5, 2020
04:12PM EST  Profound Medical Q3 EPS $(0.43) Up From $(0.57) YoY, Sales $2.98M Up From $682.22K YoY   Benzinga
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Oct 15, 2020
04:30PM EDT  Profound Medical to Release Third Quarter 2020 Financial Results   GlobeNewswire Inc
Sep 15, 2020
09:01AM EDT  Jefferies Initiates Coverage On Profound Medical with Buy Rating   Benzinga
Sep 10, 2020
11:46AM EDT  Lake Street Initiates Coverage On Profound Medical with Buy Rating, Announces Price Target of $22   Benzinga
Sep 9, 2020
04:30PM EDT  Profound Medical to Present at the Cantor Virtual Global   GlobeNewswire Inc
Aug 10, 2020
08:00AM EDT  Profound Medical Present at the Canaccord Genuity 40th Annual   GlobeNewswire Inc
Aug 6, 2020
04:33PM EDT  Profound Medical Q2 EPS $(0.46) Up From $(0.54) YoY, Sales $1.42M Up From $574.11K YoY   Benzinga
Jul 22, 2020
08:00AM EDT  Profound Medical to Release Second Quarter 2020 Financial Results   GlobeNewswire Inc
Jul 21, 2020
12:35PM EDT  Profound Medical Announces Closing of Offering   GlobeNewswire Inc
Jul 17, 2020
05:08AM EDT  64 Biggest Movers From Yesterday   Benzinga
Jul 16, 2020
06:18AM EDT  Profound Medical Prices 2.7M Share Offering of Common Shares @$14.50/Share   Benzinga
Jul 15, 2020
08:59PM EDT  Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (Profound or the Company) is pleased to announce the pricing of an underwritten public offering (the Offering) of 2,758,621 common shares of the Company (the Common Shares), at a price of US$14.50 per Common Share (the Offering Price).   GlobeNewswire Inc
04:02PM EDT  Profound Medical Reports Common Stock Offering, No Size Disclosed   Benzinga
04:01PM EDT  Profound Medical Announces Proposed Offering of Common Shares   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC